Literature DB >> 11378970

Blood donors infected with the hepatitis B virus but persistently lacking antibodies to the hepatitis B core antigen.

S Laperche1, C Guitton, W Smilovici, A M Courouce.   

Abstract

BACKGROUND AND OBJECTIVES: Antibodies to the core of hepatitis B virus (anti-HBc) are considered to be the best serologically reliable markers of hepatitis B virus (HBV) infection. Through a national epidemiological survey, two young and first-time blood donors, originating from HBV-endemic areas, were identified as HBV carriers with an absence of anti-HBc reactivity.
MATERIALS AND METHODS: We followed up these two subjects in order to investigate the evolution of their HBV serological profiles. Nucleotide sequencing was performed of the entire pre-C/C region of the strains infecting these donors.
RESULTS: The same serological profile of active viral replication with an apparent persistent lack of anti-HBc and normal alanine aminotransferase (ALT) levels was found for both subjects throughout a follow-up of 19 months and 4 months, respectively. Neither donor was immunocompromised. Nucleotide sequence analysis of the pre-C/C region did not show mutations or deletions in encoded proteins.
CONCLUSION: The hypothesis of an in utero HBV infection responsible for an immune tolerance to HBV seems to be the most probable explanation for this particular immunological situation. Such occurrences in the blood donor population are probably rare as less than 0.1% of hepatitis B surface antigen (HBsAg)-positive donors exhibit such a profile, in our experience. Moreover, this phenomenon does not impose a risk of HBV transmission by blood donation, as the exclusion of HBV-infected blood donation is based on HBsAg detection. However, such a risk might be encountered with the hepatitis C virus (HCV) for which at present only antibodies to HCV are screened.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378970     DOI: 10.1046/j.1423-0410.2001.00016.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  9 in total

Review 1.  The underlying mechanisms for the "isolated positivity for the hepatitis B surface antigen (HBsAg)" serological profile.

Authors:  Robério Amorim de Almeida Pondé
Journal:  Med Microbiol Immunol       Date:  2010-05-11       Impact factor: 3.402

2.  Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection.

Authors:  V Avettand-Fenoel; D Thabut; C Katlama; T Poynard; V Thibault
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 3.  New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.

Authors:  Mary C Kuhns; Michael P Busch
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

4.  De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor.

Authors:  Harjot K Bedi; Roberto Trasolini; Christopher F Lowe; Trana Hussaini; Mark Bigham; Gordon Ritchie; Eric M Yoshida
Journal:  Hepatol Forum       Date:  2021-09-15

5.  Hepatitis B virus genotype E surface antigen detection with different immunoassays and diagnostic impact of mutations in the preS/S gene.

Authors:  Christophe M Olinger; Bernard Weber; Jesse A Otegbayo; Wim Ammerlaan; Natascha van der Taelem-Brulé; Claude P Muller
Journal:  Med Microbiol Immunol       Date:  2007-05-15       Impact factor: 3.402

6.  Low rates of hepatitis B virus screening at the onset of chemotherapy.

Authors:  Jessica P Hwang; Michael J Fisch; Hong Zhang; Michael A Kallen; Mark J Routbort; Lincy S Lal; John M Vierling; Maria E Suarez-Almazor
Journal:  J Oncol Pract       Date:  2012-06-12       Impact factor: 3.840

Review 7.  Atypical serological profiles in hepatitis B virus infection.

Authors:  Robério A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-29       Impact factor: 3.267

Review 8.  Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures?

Authors:  Daniel Candotti; Syria Laperche
Journal:  Front Med (Lausanne)       Date:  2018-02-21

9.  HBsAg-Negative, Anti-HBc-Negative Patients Still Have a Risk of Hepatitis B Virus-Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma.

Authors:  Hyunsung Park; Do Young Kim; Soo-Jeong Kim; Haerim Chung; Hyunsoo Cho; Ji Eun Jang; June-Won Cheong; Yoo Hong Min; Jae-Woo Song; Jin Seok Kim
Journal:  Cancer Res Treat       Date:  2017-12-04       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.